CaspoNEB: Efficacy and Safety of Caspofungin Aerosols for the Curative Treatment of Pneumocystis Pneumonia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
To assess the efficacy of administrating daily caspofungin aerosols versus placebo for seven days, in adjunction of conventional systemic antifungal therapy during curative treatment of Pneumocystis pneumonia, on the clinical outcome at the end of the nebulized therapy, in order to support a \"GO / NO GO\" decision towards a phase III trial of nebulized caspofungin in those patients.
Epistemonikos ID: 4d347e38fbec3e8a22f941462382be07eb247899
First added on: Mar 26, 2025